Prof. Fernando López-Ríos (NTRK CONNECT) has developed this resource with COR2ED.
Prof. Fernando López-Ríos (NTRK CONNECT) has developed this resource with COR2ED.
Fernando Lopez-Rios is the Chief of the Molecular Diagnostics Service at Hospital Universitario 12 de Octubre (Madrid) and Professor of Pathology at Universidad Complutense (Madrid).
Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at HM Hospitales (Spain) and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York).
He is the 2023 recipient of the Mary J. Matthews Pathology & Transitional Research Award (International Association for the Study of Lung Cancer, IASLC) and the Deputy Chair of the IASLC Pathology Committee.
His main clinical and research expertise is in cancer biomarker testing.
AstraZeneca, Bayer, BMS, Lilly, MSD, Pfizer, Roche, Takeda and Thermo Fisher.
Optimising treatment strategies and AE management
Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer
An overview of the EMERALD subgroup analyses
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC
Survey findings presented at ONS 2025 and published in the journal Healthcare